(DNA) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
May 22, 2013
(Wall Street Daily,
5/21/12)
Each Friday for the last month I’ve compiled a brief rundown of a few technology stories that I’d been tracking for throughout the week.
Following...(read more)
(Penny Stock DD,
6/22/11)
Swiss pharmaceutical giant Roche Holding AG's (RHHBY.PK:News ) unit Genentech Monday stated that its investigational drug vismodegib showed positive results...(read more)
(Penny Stock DD,
4/30/11)
A drug that costs about $50 a dose is just as effective at preserving and improving vision in elderly people with an age-related eye disease as one that costs $2,000 a dose, according to the...(read more)
Genentech (DNA) Company Overview
Genentech (NYSE: DNA) is a biotech company focused on cancer treatments. Auto-immune drug Rituxan and cancer drugs Avastin and Herceptin are the company's best-selling drugs and account for more than half of revenue. The company has been number one in U.S. oncology sales since 2006.[1]
On July 21, 2008, Swiss pharmaceutical company Roche offered to buy Genentech completely for $43.7 billion, or $89 per share. Roche already owns a 55 percent stake in the company.[2] Genentech had rejected the first offer as too low, but on January 30, 2009, Roche submitted another bid, this time hostile. Roche offered shareholders $86.50 a share, down from the previous $89. [3]
(Read more at Wikinvest
) 